The biomimetic technology report by BIS
Research, shares a glimpse of the market in terms of growth potential, regional
& country wise growth, and the overall market share of each of the segments
in which the market has been categorized for the purpose of study. The report
also elucidates about the competitive scenario of the market, competitive
strength of key players in the market, and the strategies followed by them to
enter and sustain in the market.
Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market . However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030. Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chron...

Comments
Post a Comment